Deletion or mutation of IKAROS (IKZF1) is associated with minimal residual disease in BCR-ABL1-positive ALL, a poor outcome as well as high relapse rate in B-cell-progenitor ALL (60). This evidence concerns the gene IKZF1 and acute lymphoblastic leukemia.